Effect of Amino Acids and Sugar Alcohols on Satiation Peptides and Activation of Specific Brain Regions
NCT ID: NCT02823249
Last Updated: 2017-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2014-05-31
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1.56 g L-Tryptophan
1.56 g L-Tryptophan in 300 mL tap water given via nasogastric tube
\+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube
1.56 g L-Tryptophan
Tap water
Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)
Nasogastric Tube
1.56 g L-Leucine
1.56 g L-Leucine in 300 mL tap water given via nasogastric tube
\+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube
1.56 g L-Leucine
Tap water
Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)
Nasogastric Tube
50 g Xylitol
50 g Xylitol in 300 mL tap water given via nasogastric tube
50 g Xylitol
Tap water
Nasogastric Tube
75 g Erythritol
75 g Erythritol in 300 mL tap water given via nasogastric tube
75 g Erythritol
Tap water
Nasogastric Tube
75 g Glucose and mixed liquid meal
75 g Glucose in 300 mL tap water given via nasogastric tube
\+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube
75 g Glucose
Tap water
Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)
Nasogastric Tube
Tap water and mixed liquid meal
300 mL tap water given via nasogastric tube
\+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube
Tap water
Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)
Nasogastric Tube
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
1.56 g L-Tryptophan
1.56 g L-Leucine
50 g Xylitol
75 g Erythritol
75 g Glucose
Tap water
Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)
Nasogastric Tube
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy obese subjects with a body-mass index of \> 30
* Normal eating habits (no diets; no dietary changes; no special dietary habits such as vegetarian/vegan)
* Age 18-40 years
* Stable body weight for at least three months
Exclusion Criteria
* Substance abuse
* Regular intake of medications (except for oral contraceptives)
* Medical or psychiatric illness
* History of gastrointestinal disorders
* Food allergies
* Pregnancy, breast feeding
* Body piercings that cannot be removed
* History of claustrophobia
* Left-hander
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christoph Beglinger, Prof.
Role: STUDY_CHAIR
University Hospital, Basel, Switzerland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Basel
Basel, Canton of Basel-City, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
fMRI Aminoacids
Identifier Type: -
Identifier Source: org_study_id